Thursday , October 17 2019
Breaking News
Home / BUSINESS / EQUITIES / Aurobindo Pharma launches Cinacalcet Hydrochloride Tablets

Aurobindo Pharma launches Cinacalcet Hydrochloride Tablets

Aurobindo Pharma has launched Cinacalcet Hydrochloride Tablets (30mg, 60mg and 90mg) at risk in the US market in accordance with the terms of settlement agreement with Amgen Inc. Aurobindo’s Cinacalcet Hydrochloride tablets 30mg, 60mg and 90mg is a generic version of Amgen Inc’s Sensipar tablets, Cinacalcet Hydrochloride tablets had an annual sale of approximately $1,449 million for the twelve months ending May 2019 as per IQVIA.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Click & Download Udaipur Kiran App to read Latest News